**MINUTES**

**CPIC CONFERENCE CALL**

DATE: March 6, 2014

PRESENT: Adria del Tredicic, Adriana Malheiro, Andrea Gaedigk, Cyrine Haidar, Dan Hertz, Dan Roden, Daniel Muller, Ellie McDonagh, Gillian Bell, Houda Hachad, James Hoffman, Jasmine Talameh, Jason Karnes, Jason Mayes, Jeff Bishop, Jose Agundez, Julia Barbarino, Tom Callaghan, Katrin Sangkuhl, Kevin Hicks, Kelly Caudle, Kristen Weitzel, Laura Ramsey, Marc Williams, Mary Relling, Mia Wadelius, Michelle Elliot, Michelle Whirl-Carrillo, Philip Empey, Rachel Tyndale, Ravie Kem, Robert Freimuth, Steven Scherer, Steve Leeder, Stuart Scott, Sunday Obri, Teri Klein, Todd Skaar, Vicky Pratt, Vojtech Huser

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| SLCO1B1-simvastatin guideline update | Laura Ramsey (first author) discussed the SLCO1B1-simvastatin guideline update, specifically Table 1 and 2 and additions to original guideline manuscript (*i.e*. role of *SLCO1B1* genotype and other statin-induced myopathies) and supplement (*i.e*. update of frequency and evidence tables, and FDA recommendation). Cyrine Haidar discussed the addition of resources (figures and tables) to facilitate incorporation of SLCO1B1 pharmacogenetics into an electronic health record with clinical decision support. CPIC members provided feedback. Plan to submit this guideline to *CPT* in late March. Will circulate the guideline to CPIC members for review and feedback. | Kelly will circulate final guideline draft to CPIC members for comments/edits. Please send all guideline comments/edits to [Kelly.caudle@stjude.org](mailto:Kelly.caudle@stjude.org) by March 24th. |
| Possible new gene-drug guidelines | Discussed and agreed to recommend to Steering Committee to add CYP2C19 and voriconazole to CPIC drug/gene list. If you have expertise in this area and you are interested in contributing to the writing committee, please contact Kelly (Kelly.caudle@stude.org). | Kelly will coordinate writing of guideline and schedule conference call with all interested authors to establish authorship plan.  As soon as a guideline plan is confirmed, PharmGKB will add to drug/gene pair list on website. Kelly will follow-up. |
| Functional status terminology survey | All CPIC guidelines contain a table describing the association between allelic variants and functional status of the variants. However, each guideline to date has used different functional status terms (e.g., reduced function vs decreased activity, etc.). Discussed best approach to standardize these terms across CPIC guidelines; this has been an ongoing area of interest for the CPIC Informatics subcommittee and its members. Kelly is creating a survey that will be used to poll CPIC members for their opinion/ideas of how to best standardize these terms. | Contact Kelly with any ideas/ suggestions (Kelly.caudle@stjude.org). |
| New CFTR-Ivacaftor FDA label | Since the publication of the CPIC CFTR-Ivacaftor guideline, the indication section of the FDA-approved label for ivacaftor has been amended to include more CFTR variants along with G551D:  <http://www.pharmgkb.org/label/PA166104890>. PharmGKB has added a statement to the ivacaftor PharmGKB webpage (http://www.pharmgkb.org/drug/PA165950341) noting this amendment. The authors of this guideline will discuss the best approach for updating the information on PharmGKB. | Kelly will contact guideline authors and work with PharmGKB to update the content accordingly. |
| CPIC informatics working group update | - SLCO1B1-simvastatin translation tables and implementation figures/tables complete and added to guideline supplement.  -Kelly and Michelle finalizing figures/tables for the CYP2C9/HLA-B-phenytoin guideline. | James, Michelle, and Bob will continue to update CPIC group on progress. |